Anti-PD1 therapy alters the immune microenvironment of brain metastases


Neoadjuvant therapy with anti-PD1 therapy remodels the immune microenvironment of brain metastases (BMs), researchers say.

The use of neoadjuvant anti-PD1 therapy has been shown to be effective in controlling BMs of melanoma and non-small cell lung cancer, and has modest efficacy in patients with recurrent glioblastoma (rGBM), according to Dr Lu Sun of the University of California Los Angeles, USA.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.